TMSP(SH:600671) Xin Lang Cai Jing·2025-10-23 05:37Core Viewpoint - Tianmu Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 111.05%, but a recent decline of 4.63% over the past five trading days [1][2]. Financial Performance - For the first half of 2025, Tianmu Pharmaceutical achieved operating revenue of 104 million yuan, representing a year-on-year growth of 73.97%. The net profit attributable to the parent company was 10.25 million yuan, reflecting a year-on-year increase of 155.39% [2]. Stock Market Activity - As of October 23, Tianmu Pharmaceutical's stock price was 18.53 yuan per share, with a market capitalization of 2.257 billion yuan. The stock saw a trading volume of 36.016 million yuan and a turnover rate of 1.58% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on August 21, where it recorded a net buy of -55.03 million yuan [1]. Shareholder Information - As of September 19, the number of shareholders for Tianmu Pharmaceutical was 10,400, an increase of 3.21% from the previous period. The average number of circulating shares per shareholder was 11,690, a decrease of 3.11% [2]. Business Overview - Tianmu Pharmaceutical, established on June 1, 1992, and listed on August 23, 1993, is located in Hangzhou, Zhejiang Province. The company's main business includes pharmaceutical manufacturing, drug distribution, and traditional Chinese medicine diagnosis and treatment. The revenue composition is as follows: health products 48.01%, circulating goods 23.21%, raw materials 15.98%, traditional Chinese medicine 11.47%, Western medicine 0.89%, training 0.32%, and others 0.12% [1][2]. Dividend Information - Since its A-share listing, Tianmu Pharmaceutical has distributed a total of 59.6313 million yuan in dividends, with no dividends paid in the last three years [3].